| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/29/2008 | US20080124300 stabilizing honey bee brood pheromone comprised of two or more of 16-20-carbon carboxylic acids, or their methyl or ethyl esters by incorporating an antioxidant |
| 05/29/2008 | US20080124297 Hydrolytically cleaving a plurality of peptide bonds in an allergenic polypeptide, using enzymes to denature all allergens; treating asthma, allergic rhinitis and atopic eczema in both humans and animals |
| 05/29/2008 | US20080124285 Merocyanine Derivatives for Cosmetic Use |
| 05/29/2008 | US20080124280 Thyroid Hormone Analogs and Methods of Use |
| 05/29/2008 | US20080124277 Human and Mouse Targeting Peptides Identified by Phage Display |
| 05/29/2008 | US20080124270 Compounds Useful as Metal Chelators |
| 05/29/2008 | DE112005001269T5 Polysaccharidextrakt aus Lycium barbarum als neuroprotektives Mittel gegen ß-Amyloidpeptidneurotoxizität Lycium barbarum from Polysaccharidextrakt as a neuroprotective agent against beta-amyloid peptide toxicity EUR |
| 05/29/2008 | DE102006056458A1 Arzneimittelzubereitung von Tramadol und Acetaminophen The pharmaceutical preparation of tramadol and acetaminophen |
| 05/29/2008 | DE102006054757A1 Neue aza-bicyclische Verbindungen und ihre Verwendung New aza-bicyclic compounds and their use |
| 05/29/2008 | DE102006054205A1 Verwendung von Cytohesin-Inhibitoren zur chemischen Induktion von Langlebigkeit Use of Cytohesin inhibitors for chemical induction of longevity |
| 05/29/2008 | DE10113974B4 Verwendung von racemischer und enantiomerenreiner Dihydroliponsäure oder deren Derivate zur Körpergewichtsreduzierung und/oder zur Verringerung des Appetits The use of racemic and enantiomerically pure dihydrolipoic acid or their derivatives for body weight reduction and / or for the reduction of appetite |
| 05/29/2008 | CA2749074A1 Process for the preparation of sevelamer hydrochloride and formulation thereof |
| 05/29/2008 | CA2706070A1 Therapeutic tetrahydroisoquinoline-based compositions for cancer therapy |
| 05/29/2008 | CA2689293A1 Prostaglandin prodrugs |
| 05/29/2008 | CA2679955A1 Novel chemotherapeutic agents against inflammation and cancer |
| 05/29/2008 | CA2677335A1 Indozalyl sulphonamide derivatives useful as glucocorticoid modulators |
| 05/29/2008 | CA2674359A1 Metabolically-stabilized inhibitors of fatty acid amide hydrolase |
| 05/29/2008 | CA2673137A1 Prodrug salts of 2,4-pyrimidinediamine compounds and their uses |
| 05/29/2008 | CA2671517A1 Method of radio-sensitizing tumors using a radio-sensitizing agent |
| 05/29/2008 | CA2670846A1 Pharmaceutical compositions for the treatment of capillary arteriopathy |
| 05/29/2008 | CA2670619A1 Dissolution and processing of cellulose |
| 05/29/2008 | CA2670468A1 Melatonin derivatives and their use as antioxidants |
| 05/29/2008 | CA2670439A1 Anticonvulsive pharmaceutical compositions |
| 05/29/2008 | CA2670418A1 N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimers's |
| 05/29/2008 | CA2670417A1 Tricarbonyl complexes with tridentate chelators for myocardium imaging |
| 05/29/2008 | CA2670409A1 Compositions and methods of using same for treatment of a disease or disorder of the eye and/or the adnexa of the eye |
| 05/29/2008 | CA2670405A1 Combination treatments for alzheimer's disease and related neurodegenerative diseases |
| 05/29/2008 | CA2670404A1 Heteromonocyclic compound and use thereof |
| 05/29/2008 | CA2670382A1 (r)-n-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs |
| 05/29/2008 | CA2670362A1 Compounds modulating c-fms and/or c-kit activity and uses therefor |
| 05/29/2008 | CA2670340A1 Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators |
| 05/29/2008 | CA2670328A1 Nucleoside aryl phosphoramidates and their use as anti-viral agents for the treatment of hepatitis c virus |
| 05/29/2008 | CA2670290A1 Transdermal therapeutic system for administering the active substance buprenorphine |
| 05/29/2008 | CA2670288A1 Methods of treating chronic inflammatory diseases using a gm-csf antagonist |
| 05/29/2008 | CA2670276A1 Compounds useful for treating neurodegenerative disorders |
| 05/29/2008 | CA2670207A1 Process for preparing a crystalline form of candesartan cilexetil |
| 05/29/2008 | CA2670202A1 5-sulfanylmethyl-[1,2,4] triazol[1, 5-a] pyrimidin-7-ol derivatives as cxcr2 antagonists |
| 05/29/2008 | CA2670165A1 2- [ (2-substituted) -ind0lizin-3-yl] -2-oxo-acetamide derivatives as antifungal agents |
| 05/29/2008 | CA2670160A1 Methods for improving bioavailability of a renin inhibitor |
| 05/29/2008 | CA2670157A1 Delivery system for risperidone |
| 05/29/2008 | CA2670153A1 Stable powder formulation containing a novel anticholinergic agent |
| 05/29/2008 | CA2670143A1 Pyrimidines and their use as cxcr2 receptor antagonists |
| 05/29/2008 | CA2670136A1 7,8-saturated-4,5-epoxy-morphinanium analogs |
| 05/29/2008 | CA2670099A1 Synthesis and biological activities of new tricyclic-bis-enones (tbes) |
| 05/29/2008 | CA2670083A1 Heterobicyclic metalloprotease inhibitors |
| 05/29/2008 | CA2670044A1 Heterobicyclic matrix metalloprotease inhibitors |
| 05/29/2008 | CA2670042A1 Heterobicyclic matrix metalloprotease inhibitors |
| 05/29/2008 | CA2670031A1 Heterobicyclic metalloprotease inhibitors |
| 05/29/2008 | CA2670026A1 Heterotricyclic metalloprotease inhibitors |
| 05/29/2008 | CA2669991A1 Imidazotriazines and imidazopyrimidines as kinase inhibitors |
| 05/29/2008 | CA2669982A1 Combination therapy for proliferative disorders |
| 05/29/2008 | CA2669935A1 Methods for preserving renal function using xanthine oxidoreductase inhibitors |
| 05/29/2008 | CA2669888A1 Novel aza-bicyclic compounds and their use as stimulators of soluble guanylate cyclase |
| 05/29/2008 | CA2669887A1 Metallo-oxidoreductase inhibitors using metal binding moieties in combination with targeting moieties |
| 05/29/2008 | CA2669856A1 Hepatitis c virus inhibitors |
| 05/29/2008 | CA2669846A1 Materials and methods for introducing genetic material into living cells |
| 05/29/2008 | CA2669839A1 2-hydroxy-1,3-diaminopropane derivatives |
| 05/29/2008 | CA2669833A1 Vaginal delivery system for mirtazapine |
| 05/29/2008 | CA2669705A1 Stable parenteral formulation containing a rsv inhibitor of a benzodiazepine structure |
| 05/29/2008 | CA2669579A1 5-sulfanylmethyl-pyrazolo [1,5-a] pyrimidin-7-ol derivatives as cxcr2 antagonists |
| 05/29/2008 | CA2669447A1 Allosteric modulators of the a1 adenosine receptor |
| 05/29/2008 | CA2669300A1 Use of arginase inhibitors in the treatment of asthma and allergic rhinitis |
| 05/29/2008 | CA2669229A1 Method of treatment for inflammatory bowel disease |
| 05/29/2008 | CA2669209A1 Use of lipid containing particles comprising quillaja saponins for the treatment of cancer |
| 05/29/2008 | CA2669199A1 Salts and crystal forms of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile |
| 05/29/2008 | CA2669124A1 Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity |
| 05/29/2008 | CA2669104A1 Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity |
| 05/29/2008 | CA2669102A1 Tetralin analogs having sphingosine 1-phosphate agonist activity |
| 05/29/2008 | CA2669094A1 Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions |
| 05/29/2008 | CA2669084A1 Pak modulators |
| 05/29/2008 | CA2669083A1 5, 6, or 7-substituted-3-(hetero)arylisoquinolinamine derivatives as antitumor agents |
| 05/29/2008 | CA2668828A1 Crystalline forms of aliskiren hemifumarate |
| 05/29/2008 | CA2668757A1 Composition for inhibiting nadph oxidase activity |
| 05/29/2008 | CA2668661A1 Substituted pyrazole and triazole compounds as ksp inhibitors |
| 05/29/2008 | CA2668652A1 Inhibitors of voltage-gated ion channels for use in treating pain and pruritis |
| 05/29/2008 | CA2668471A1 Antioxidant dietary supplement compositions and methods for maintaining healthy skin |
| 05/29/2008 | CA2668441A1 Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
| 05/29/2008 | CA2668369A1 5-hydroxymethyl-oxazolidin-2-one antibacterials |
| 05/29/2008 | CA2668205A1 2-alkyl-indazole compounds for the treatment of certain cns-related disorders |
| 05/29/2008 | CA2667494A1 Dual action, inhaled formulations providing both an immediate and sustained release profile |
| 05/29/2008 | CA2666814A1 Combination therapy for treatment of viral infections |
| 05/29/2008 | CA2666689A1 Medical device coatings and coated stents |
| 05/29/2008 | CA2666405A1 Improved process for the preparation of (r)-(+)-4-(ethyiamino)-3,4-dihydro-2-(3- methoxypropyl)-2h-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide |
| 05/29/2008 | CA2666371A1 Use of an indazolemethoxyalkanoic acid to prepare a pharmaceutical composition |
| 05/29/2008 | CA2666224A1 Boronic acids and esters as inhibitors of fatty acid amide hydrolase |
| 05/29/2008 | CA2666159A1 Novel crystal of (s)-(+)-2-(2-chlorophenyl)-2-hydroxy-ethyl carbamate |
| 05/29/2008 | CA2665726A1 Pharmaceutical compositions |
| 05/29/2008 | CA2665223A1 An enzyme regulating ether lipid signaling pathways |
| 05/29/2008 | CA2665214A1 Novel imidazothiazoles and imidazoxazoles |
| 05/29/2008 | CA2664126A1 The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of cns disorders |
| 05/29/2008 | CA2662510A1 Transdermal therapeutic system with high rate of utilization of active substance and dosing accuracy |
| 05/29/2008 | CA2658834A1 Bisphosphonate inhalant formulations and methods for using the same |
| 05/29/2008 | CA2655310A1 Use of a2a adenosine receptor agonists in the treatment of ischemia |
| 05/29/2008 | CA2650227A1 Substituted pyrazolopyrimidines |
| 05/29/2008 | CA2636242A1 Heterobicyclic thiophene compounds and methods of use |
| 05/28/2008 | EP1925941A1 Method for prediction of the efficacy of vascularization inhibitor |
| 05/28/2008 | EP1925677A2 Marker genes for determining renal toxicity |
| 05/28/2008 | EP1925676A1 Method for assay on the effect of vascularization inhibitor |
| 05/28/2008 | EP1925665A1 Use of non-viral active agents manufactured with a molecular-biological method for treating acne |
| 05/28/2008 | EP1925624A1 Use of squalenic acid for the formulation of an active principle in nanoparticle state |